The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis - A randomized controlled trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514055-15-00

Acronym

NL71782.078.19

Enrollment

132

Registered

2024-11-19

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary sarcoidosis

Brief summary

Change in hospital-measured Forced Vital Capacity

Detailed description

Biomarkers

Interventions

DRUGMETHOTREXATE

DRUGPREDNISONE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in hospital-measured Forced Vital Capacity	—

Secondary

Measure	Time frame
Biomarkers	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026